ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3164

Calcium Pyrophosphate Deposition Disease and Associated Medical Co-Morbidities in the Veteran Population

Crystal Kleiber Balderrama1, Daniel S. Lans2, Ann K. Rosenthal1,3 and Christie M. Bartels4, 1Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, 2Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI, 3Division of Rheumatology, Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI, 4Medicine, Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Calcium pyrophosphate dihydrate (CPPD), chondrocalcinosis and pseudogout, Co-morbidities

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Metabolic and Crystal Arthropathies II: Mechanisms and Associations

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Title:  Calcium
Pyrophosphate Deposition Disease and Associated Medical Co-Morbidities in the
Veteran Population. 

Background/Purpose:   Precipitation of calcium pyrophosphate dihydrate (CPP) crystals in articular tissues results in a
variety of clinical presentations collectively called CPP crystal deposition
disease (CPPD).  The cause of CPPD remains unknown and no evidence-based
treatments are available. Some risk factors for CPPD have been identified
including aging, prior joint trauma, and various metabolic conditions. The
objective of this study was to identify patient characteristics and medical
conditions associated with CPPD in the veteran population using data from the
Veteran Affairs’ (VA) Corporate Data Warehouse using previously validated ICD-9
codes.

Methods:   This cross-sectional case control
study included patients seen at any VA medical center from 2010 through 2014
with ICD-9 codes for CPPD. Cases were age-matched with a control population
that also received care at a VA facility in the same time frame and lacked
ICD-9 codes for CPPD.  Prevalences of various
co-morbidities were examined in each cohort.  Univariate
odds ratios were computed to examine the association between CPPD and each
condition.

Results:   A total of 54,564 (27,282 CPPD cases;
27,282 Controls) patients were included (Table 1). The conditions having the
strongest associations with CPPD included osteoarthritis (OR, 3.71; CI, 3.58 to
3.85), gout (OR, 3.11; CI, 2.97 to 3.26), hyperparathyroidism (OR, 4.31; CI,
3.76 to 4.94), rheumatoid arthritis (OR, 3.43; CI, 3.13 to 3.75), and
hemochromatosis (OR, 2.29; CI, 1.86 to 2.81). Hypothyroidism, hypomagnesemia, diabetes, and chronic kidney disease did
not appear to be associated with the disease. Knee, shoulder, and hip arthroplasties were more common in the CPPD cohort. 

Conclusion:   This data set contains the largest
study population of CPPD patients examined to date. We confirm known disease
associations with conditions such as osteoarthritis, gout, hemochromatosis, and
hyperparathyroidism.  Interestingly, there was not a significant
association between CPPD and hypothyroidism, chronic kidney disease, or
diabetes, and the difference in rates of hypomagnesemia
was not statistically significant.  In contrast, an interesting association
with rheumatoid arthritis was noted which could reflect diagnostic mimicry or
concomitant disease.  CPPD patients also had higher rates of total joint
replacements, particularly for knee arthroplasty. We
anticipate that this data set could shed additional light on this understudied
disease.

 

 


Disclosure: C. Kleiber Balderrama, None; D. S. Lans, None; A. K. Rosenthal, None; C. M. Bartels, Pfizer Inc, 2.

To cite this abstract in AMA style:

Kleiber Balderrama C, Lans DS, Rosenthal AK, Bartels CM. Calcium Pyrophosphate Deposition Disease and Associated Medical Co-Morbidities in the Veteran Population [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/calcium-pyrophosphate-deposition-disease-and-associated-medical-co-morbidities-in-the-veteran-population/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/calcium-pyrophosphate-deposition-disease-and-associated-medical-co-morbidities-in-the-veteran-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology